Application of aminothiazole derivative in preparation of medicine for treating alcoholic liver disease

By targeting the aminothiazole derivative INNA1605, which inhibits the proinflammatory signaling pathway of TLRs-Myd88-NF-κB, the problem of lack of effective drugs for the treatment of alcoholic liver disease in the prior art is solved, and effective relief of inflammation of alcoholic liver disease is achieved and Improvement of the inflammatory microenvironment of the liver has potential therapeutic prospects.

CN118903134APending Publication Date: 2024-11-08WUHAN YINGNUO PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411246518.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

There is a lack of effective drugs for treating alcoholic liver disease in the prior art, especially the regulatory effect of inflammation in alcoholic liver disease, and the application of the existing aminothiazole derivative INNA1605 has not been explored in this field.

Method used

By targeting the inhibition of the activation of MyD88 molecule in the TLRs-Myd88-NF-κB proinflammatory signaling pathway, an aminothiazole derivative was developed as an inflammatory inhibitor for the preparation of preventing, relieving or treating alcoholic liver disease, with specific compounds of 3- (4-benzylpiperazine-1-yl)-N-(4-phenylthiazole-2-yl)propanamide, code INNA1605.

Benefits of technology

This aminothiazole derivative can effectively inhibit the inflammatory signaling in alcoholic liver disease, relieve the liver inflammation process caused by excessive drinking, improve the alcohol-induced inflammatory microenvironment of liver disease, and achieve the effect of treating alcoholic liver disease and show safety good.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903134A_ABST
    Figure CN118903134A_ABST
Patent Text Reader

Abstract

The invention relates to the field of biological medicine, in particular to application of an aminothiazole derivative in medicine for preventing, relieving or treating alcoholic liver diseases, and the aminothiazole derivative achieves the effect of inhibiting inflammation signal transduction by targeted inhibition of activation of MyD88 molecules in a TLRs-Myd88-NF-kappa B pro-inflammatory signal channel in the alcoholic liver diseases. The inflammatory process of the alcoholic liver disease caused by excessive drinking can be relieved, and the liver inflammatory microenvironment induced by alcohol is improved, so that the effect of treating the alcoholic liver disease is achieved. According to the invention, INNA1605 is used for inhibiting alcohol-induced liver inflammation for the first time so as to improve the alcoholic liver disease, a foundation is laid for further drug research and development, and the application has a potential treatment application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of biomedicine, and in particular to the application of an aminothiazole derivative in the preparation of a drug for treating alcoholic liver disease. Background Art

[0002] Alcoholic liver disease caused by chronic excessive drinking Alcoholic liver disease is a wide range of liver diseases, ranging from simple fatty degeneration to more severe damage such as steatohepatitis, cirrhosis and hepatocellular carcinoma. About 5%-40% of patients with alcoholic liver disease may develop alcoholic hepatitis (AH), which is characterized by liver damage, inflammation and fibrosis. Alcohol is mainly absorbed in the small intestine and metabolized by the liver after entering the blood. Alcohol can cause liver cell damage. In the early stage of alcoholic liver damage, the damage-associated molecular patterns (DAMPs) released by damaged and dead liver cells together with portal pathogen-associated molecular patterns (PAMPs) (such as lipopolysaccharide (LPS)) caused by intestinal barrier damage stimulate the activation of liver macrophages through TLRs and NOD-like receptors, and then transmit inflammatory signals through the TLRs-MyD88-NF-κB inflammatory signal cascade, followed by the production of a variety of inflammatory cytokines / chemokines, such as IL-6, TNF-α, IL-1β and CCL2; at the same time, long-term drinking changes the composition of intestinal flora, the flora ratio is imbalanced, and the flora products also change, entering the liver through the damaged intestinal barrier, activating macrophages and causing inflammation. It can be seen that inflammation plays an important role in the occurrence and development of alcoholic liver disease. At present, the main clinical treatment methods include: abstinence from alcohol, nutritional support, glucocorticoid anti-inflammatory, metadoxine to promote alcohol metabolism, liver protection (S-adenosylmethionine, polyene phosphatidylcholine, glycyrrhizic acid preparations, silymarin and reduced glutathione, bicyclol) ​​and anti-fibrosis treatment.

[0003] The prior art provides an aminothiazole derivative INNA1605, whose structure and function are disclosed in the Chinese invention patent CN201110049687.4 "2-aminothiazole derivatives and preparation methods and applications". This type of small molecule compound inhibits the dimerization of the TIR domain of the MyD88 protein, thereby blocking the activation of NF-кB, thereby producing an immunosuppressive effect, and has therapeutic effects in anti-transplant rejection, anti-autoimmune diseases, anti-ischemia reperfusion injury, anti-chronic inflammatory response, and anti-endotoxinemia. However, there is no research on the regulatory effect of INNA1605 on alcoholic liver disease. Summary of the invention

[0004] In order to overcome the shortcomings of the above-mentioned technology, the purpose of the present invention is to provide an aminothiazole derivative for use in the preparation of a drug for treating alcoholic liver disease. The aminothiazole derivative of the present invention inhibits the activation of MyD88 molecules in the TLRs-Myd88-NF-κB pro-inflammatory signaling pathway in alcoholic liver disease, thereby inhibiting the conduction of inflammatory signals, alleviating the inflammatory process of alcoholic liver disease caused by excessive drinking, and improving the alcohol-induced liver inflammatory microenvironment, thereby achieving the effect of treating alcoholic liver disease.

[0005] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0006] The present invention provides the use of aminothiazole derivatives in preparing drugs for preventing, alleviating or treating alcoholic liver disease.

[0007] The present invention also provides the use of aminothiazole derivatives in preparing inflammation inhibitors.

[0008] The present invention also provides the use of aminothiazole derivatives as inflammation inhibitors for preparing drugs for preventing, alleviating or treating alcoholic liver disease.

[0009] Preferably, the inflammation inhibitor is a TLRs-Myd88-NF-κB pro-inflammatory signaling pathway inhibitor, which can inhibit the activation of MyD88 molecules in the TLRs-Myd88-NF-κB pro-inflammatory signaling pathway to achieve the effect of inhibiting inflammatory signal transduction, alleviate the inflammatory process of alcoholic liver disease caused by excessive drinking, and improve the alcohol-induced liver inflammatory microenvironment.

[0010] The present invention also provides the use of aminothiazole derivatives as TLRs-Myd88-NF-κB pro-inflammatory signaling pathway inhibitors for preparing drugs for preventing, alleviating or treating alcoholic liver disease.

[0011] Preferably, the aminothiazole derivative is 3-(4-benzylpiperazine-1-yl)-N-(4-phenylthiazol-2-yl)propionamide, codenamed INNA1605, and has the following chemical structure:

[0012]

[0013] Preferably, the alcoholic liver disease comprises at least one of alcoholic hepatitis, alcoholic cirrhosis and alcoholic liver cancer.

[0014] Compared with the prior art, the present invention has the following beneficial effects:

[0015] The present invention randomly divides mice into four groups: control liquid feed + intragastric distilled water, control liquid feed + intragastric administration of INNA1605 (dissolved in distilled water), 5% alcohol liquid feed + intragastric administration of distilled water, and 5% alcohol liquid feed + intragastric administration of INNA1605 (dissolved in distilled water), and verifies whether the intestinal flora homeostasis is restored after intragastric administration of INNA1605; during the entire experimental process, the weight changes and dietary changes are recorded, and at the same time, pathology (HE, Oil Red O), cytokine (IL-1β, TNF-α, IL-6) Elisa and other technologies are used to detect whether the alcoholic liver disease-related changes in the four groups of mice are alleviated after intragastric administration of INNA1605. The experiment confirms that INNA1605 can alleviate the inflammatory process of alcoholic liver disease caused by excessive drinking, improve the alcohol-induced liver inflammatory microenvironment, thereby achieving the effect of treating alcoholic liver disease, and has the advantage of good safety. The present invention is the first to use INNA1605 to inhibit alcohol-induced liver inflammation to improve alcoholic liver disease, laying a foundation for further drug research and development, and has potential therapeutic application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 HE and Oil Red O staining results of mouse livers in four groups: control liquid feed + intragastric distilled water, control liquid feed + intragastric INNA1605 (dissolved in distilled water) 50 mg / kg mouse / day, 5% alcohol liquid feed + intragastric distilled water, 5% alcohol liquid feed + intragastric INNA1605 (dissolved in distilled water) 50 mg / kg mouse / day;

[0017] Figure 2 The results of the serum inflammatory factors (IL-1β, TNF-α, IL-6) levels in mice in the four groups of control liquid feed + intragastric distilled water, control liquid feed + intragastric INNA1605 (dissolved in distilled water) 50 mg / kg mouse / day, 5% alcohol liquid feed + intragastric distilled water, 5% alcohol liquid feed + intragastric INNA1605 (dissolved in distilled water) 50 mg / kg mouse / day are shown in the graph;

[0018] Figure 3 The results of serum ALT, AST, TC, and TG in mice in the four groups of control liquid feed + intragastric distilled water, control liquid feed + intragastric INNA1605 (dissolved in distilled water) 50 mg / kg mouse / day, 5% alcohol liquid feed + intragastric distilled water, and 5% alcohol liquid feed + intragastric INNA1605 (dissolved in distilled water) 50 mg / kg mouse / day;

[0019] In the figure: Con refers to the control liquid feed + intragastric distilled water group, Con 50 refers to the control liquid feed + intragastric INNA1605 (dissolved in distilled water) 50 mg / kg mouse / day group, ALD refers to the 5% alcohol liquid feed + intragastric distilled water group, ALD 50 refers to the 5% alcohol liquid feed + intragastric INNA1605 (dissolved in distilled water) 50 mg / kg mouse / day group. DETAILED DESCRIPTION

[0020] In order to better explain the present invention, the main contents of the present invention are further explained below in conjunction with specific embodiments, but the contents of the present invention are not limited to the following embodiments.

[0021] Example 1

[0022] Female C57BL / 6J mice aged 6-8 weeks were housed in an SPF barrier environment. After one week of adaptive feeding, they were randomly divided into 4 groups: control liquid feed + intragastric administration of distilled water (Group A, i.e., Con group), control liquid feed + intragastric administration of 50 mg INNA1605 (dissolved in distilled water) / kg mouse / day (Group B, i.e., Con 50 group), 5% alcohol liquid feed + intragastric administration of distilled water (Group C, i.e., ALD group), and 5% alcohol liquid feed + intragastric administration of 50 mg INNA1605 (dissolved in distilled water) / kg mouse / day (Group D, i.e., ALD 50 group).

[0023] The experimental period was 22 days in total. From the 1st day to the 7th day, adaptive feeding was carried out for one week. Different feeds and different treatments were given starting from the 8th day: on the 8th day, control liquid feed was given to Group A and Group B, and 1% alcohol liquid feed was given to Group C and Group D (prepared according to the feed formula, and different concentrations of alcohol liquid feed were prepared according to the formula); on the 9th day, control liquid feed was given to Group A and Group B, and 2% alcohol liquid feed was given to Group C and Group D; on the 10th day, control liquid feed was given to Group A and Group B, and 3% alcohol liquid feed was given to Group C and Group D; on the 11th day, control liquid feed was given to Group A and Group B, and 4% alcohol liquid feed was given to Group C and Group D; on the 12th day, control liquid feed was given to Group A and Group B, and 5% alcohol liquid feed was given to Group C and Group D; from the 13th day to the 22nd day, Group A was given a control liquid feed and an appropriate amount of distilled water was administered by gavage, and the rats were given Group B was given a control liquid feed and gavage of INNA1605 (dissolved in distilled water) 50 mg / kg mouse / day, Group C was given a 5% alcohol liquid feed and gavage of an appropriate amount of distilled water, and Group D was given a 5% alcohol liquid feed and gavage of INNA1605 (dissolved in distilled water) 50 mg / kg mouse / day; at 7-9 am on the 22nd day, Group A and Group B were gavaged with an appropriate amount of glucose solution, and Group C and Group D were gavaged with 5 mg / kg anhydrous ethanol. After 9 hours, the mice in different groups were anesthetized, their eyeballs were removed to collect blood, and serum was collected by centrifugation (subsequent testing of ALT, AST, TC, and TG), and the mouse liver was taken and fixed with 4% paraformaldehyde (subsequent testing of HE, Oil Red O, etc.) or the tissues were packaged and placed in a liquid nitrogen tank, and then placed in a -80°C refrigerator for standby use (subsequent tissue testing of qPCR and inflammatory factor Elisa).

[0024] The results are as follows Figures 1 to 3 As shown, administration of INNA1605 50 mg / kg / day can inhibit liver fatty degeneration in mice.

[0025] like Figure 1 As shown, the liver pathological results of mice showed that liver fatty degeneration was significantly improved after administration of INNA1605, and there was no toxic effect, that is, INNA1605 had no pathological damage to the liver of normal mice.

[0026] The results of the examination of mouse serum inflammatory factors are as follows Figure 2 As shown, INNA1605 can reduce the expression of inflammatory factors IL-6, IL-1β and TNA-α, and improve the inflammatory environment in vivo.

[0027] The test results of mouse serum ALT, AST, TC, TG and other indicators are as follows Figure 3 As shown, the results showed that the levels of various indicators decreased after treatment with INNA1605. These results confirm the effect of INNA1605 in inhibiting inflammation and improving alcoholic fatty liver disease.

[0028] The above-described embodiment only expresses one implementation of the present invention, and should not be construed as limiting the scope of the invention patent. It should be noted that, for those skilled in the art, several modifications and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. The use of aminothiazole derivatives in the preparation of drugs for preventing, alleviating or treating alcoholic liver disease.

2. Application of aminothiazole derivatives in the preparation of inflammation inhibitors.

3. The use of aminothiazole derivatives as inflammation inhibitors for the preparation of drugs for preventing, alleviating or treating alcoholic liver disease.

4. The use according to claim 3, characterized in that: The inflammation inhibitor is a TLRs-Myd88-NF-κB pro-inflammatory signaling pathway inhibitor, which can inhibit the activation of MyD88 molecules in the TLRs-Myd88-NF-κB pro-inflammatory signaling pathway to achieve the effect of inhibiting inflammatory signal conduction, alleviate the inflammatory process of alcoholic liver disease caused by excessive drinking, and improve the alcohol-induced liver inflammatory microenvironment.

5. The use of aminothiazole derivatives as inhibitors of the TLRs-Myd88-NF-κB pro-inflammatory signaling pathway for the preparation of drugs for preventing, alleviating or treating alcoholic liver disease.

6. The use according to any one of claims 1 to 3 and 5, characterized in that: The aminothiazole derivative is 3-(4-benzylpiperazine-1-yl)-N-(4-phenylthiazol-2-yl)propionamide, code-named INNA1605, and has the following chemical structure:

7. The use according to claim 1, characterized in that: The alcoholic liver disease includes at least one of alcoholic hepatitis, alcoholic cirrhosis, and alcoholic liver cancer.